Beta Bionics, Inc. Common Stock Cash Flow Conversion Efficiency
Beta Bionics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.62 Million) by net assets ($256.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Beta Bionics, Inc. Common Stock (2022–2025)
Cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2025. This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Beta Bionics, Inc. Common Stock (BBNX) stock price for real-time trading data and today's change.
Beta Bionics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Beta Bionics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see BBNX company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Shengyang Science
SHG:603703
|
0.010x |
|
Guangdong Wencan Die Casting Co Ltd
SHG:603348
|
0.030x |
|
Hefei Department Store Group Co Ltd
SHE:000417
|
0.042x |
|
XiAn Tian He Defense Technology Co Ltd
SHE:300397
|
-0.012x |
|
Guilin Layn Natural Ingredients Corp
SHE:002166
|
0.017x |
|
Friend Co Ltd
SHG:605050
|
N/A |
|
China Resources and Environment Co Ltd
SHG:600217
|
0.215x |
|
Klaveness Combination Carriers ASA
OL:KCC
|
0.058x |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2025. Review BBNX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.61 Million | $-50.92 Million | -0.177x | +72.12% |
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | -256.34% |
| 2022-12-31 | $-170.03 Million | $-60.21 Million | 0.354x | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more